Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases.

Uruga, Hironori; Bozkurtlar, Emine; Huynh, Tiffany G; Muzikansky, Alona; Goto, Yasushi; Gomez-Caraballo, Maria; Hata, Aaron N; Gainor, Justin F; Mark, Eugene J; Engelman, Jeffrey A; Lanuti, Michael D; Mino-Kenudson, Mari

Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases.

Uruga, Hironori; Bozkurtlar, Emine; Huynh, Tiffany G; Muzikansky, Alona; Goto, Yasushi; Gomez-Caraballo, Maria; Hata, Aaron N; Gainor, Justin F; Mark, Eugene J; Engelman, Jeffrey A; Lanuti, Michael D; Mino-Kenudson, Mari.

Afiliação

Uruga H; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
Bozkurtlar E; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
Huynh TG; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
Muzikansky A; Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.
Goto Y; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Gomez-Caraballo M; Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.
Hata AN; Cancer Center, Massachusetts General Hospital, Boston, Massachusetts; Department of Medicine, Harvard Medical School, Boston, Massachusetts.
Gainor JF; Cancer Center, Massachusetts General Hospital, Boston, Massachusetts; Department of Medicine, Harvard Medical School, Boston, Massachusetts.
Mark EJ; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts; Department of Pathology, Harvard Medical School, Boston, Massachusetts.
Engelman JA; Cancer Center, Massachusetts General Hospital, Boston, Massachusetts; Department of Medicine, Harvard Medical School, Boston, Massachusetts.
Lanuti MD; Division of Thoracic Surgery, Massachusetts General Hospital, Boston, Massachusetts; Department of Surgery, Harvard Medical School, Boston, Massachusetts.
Mino-Kenudson M; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts; Department of Pathology, Harvard Medical School, Boston, Massachusetts. Electronic address: MMINOKENUDSON@partners.org.

J Thorac Oncol ; 12(3): 458-466, 2017 03.

Article em En | MEDLINE | ID: mdl-27815126

Assuntos

Adenocarcinoma/metabolismo; Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico; Antígeno B7-H1/metabolismo; Biomarcadores Tumorais/metabolismo; Neoplasias Pulmonares/metabolismo; Recidiva Local de Neoplasia/metabolismo; Adenocarcinoma/tratamento farmacológico; Adenocarcinoma/imunologia; Adenocarcinoma/secundário; Adulto; Idoso; Idoso de 80 Anos ou mais; Apoptose; Linfócitos T CD8-Positivos/imunologia; Linfócitos T CD8-Positivos/patologia; Feminino; Seguimentos; Humanos; Neoplasias Pulmonares/tratamento farmacológico; Neoplasias Pulmonares/imunologia; Neoplasias Pulmonares/patologia; Metástase Linfática; Linfócitos do Interstício Tumoral/imunologia; Linfócitos do Interstício Tumoral/patologia; Masculino; Pessoa de Meia-Idade; Recidiva Local de Neoplasia/tratamento farmacológico; Recidiva Local de Neoplasia/imunologia; Recidiva Local de Neoplasia/patologia; Estadiamento de Neoplasias; Prognóstico; Taxa de Sobrevida

Palavras-chave

Adjuvant therapy; Lung adenocarcinoma; Lymph node metastasis; PD-L1; Programmed death-ligand 1; Tumor-infiltrating lymphocyte

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores Tumorais / Antígeno B7-H1 / Neoplasias Pulmonares / Recidiva Local de Neoplasia Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google